163 related articles for article (PubMed ID: 25250167)
1. In Silico Design and Analysis of TGFαL3-SEB Fusion Protein as "a New Antitumor Agent" Candidate by Ligand-Targeted Superantigens Technique.
Imani-Fooladi AA; Yousefi F; Mousavi SF; Amani J
Iran J Cancer Prev; 2014; 7(3):152-64. PubMed ID: 25250167
[TBL] [Abstract][Full Text] [Related]
2. Preparation and In Vitro Evaluation of Antitumor Activity of TGFαL3-SEB as a Ligand-Targeted Superantigen.
Yousefi F; Mousavi SF; Siadat SD; Aslani MM; Amani J; Rad HS; Fooladi AA
Technol Cancer Res Treat; 2016 Apr; 15(2):215-26. PubMed ID: 25759426
[TBL] [Abstract][Full Text] [Related]
3. Tagging staphylococcal enterotoxin B (SEB) with TGFaL3 for breast cancer therapy.
Yousefi F; Siadat SD; Saraji AA; Hesaraki S; Aslani MM; Mousavi SF; Imani Fooladi AA
Tumour Biol; 2016 Apr; 37(4):5305-16. PubMed ID: 26561468
[TBL] [Abstract][Full Text] [Related]
4. Growth-inhibitory effects of TGFαL3-SEB chimeric protein on colon cancer cell line.
Maleki F; Sadeghifard N; Hosseini HM; Bakhtiyari S; Goleij Z; Behzadi E; Sedighian H; Imani Fooladi AA
Biomed Pharmacother; 2019 Feb; 110():190-196. PubMed ID: 30471512
[TBL] [Abstract][Full Text] [Related]
5. TGFαL3-SEB fusion protein as an anticancer against ovarian cancer.
Maleki F; Sadeghifard N; Sedighian H; Bakhtiyari S; Hosseini HM; Fooladi AAI
Eur J Pharmacol; 2020 Mar; 870():172919. PubMed ID: 31935394
[TBL] [Abstract][Full Text] [Related]
6. Novel SPEA Superantigen Peptide Agonists and Peptide Agonist-TGFαL3 Conjugate. In Vitro Study of Their Growth-Inhibitory Effects for Targeted Cancer Immunotherapy.
Bashraheel SS; Goda SK
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445686
[TBL] [Abstract][Full Text] [Related]
7. Construction and characterization of a novel superantigen fusion protein: bFGF/SEB.
Wang L; Zhang H; Zhang S; Yu M; Yang X
Cancer Invest; 2009 May; 27(4):376-83. PubMed ID: 19160106
[TBL] [Abstract][Full Text] [Related]
8. Human TGFalpha-derived peptide TGFalphaL3 fused with superantigen for immunotherapy of EGFR-expressing tumours.
Xu Q; Zhang X; Yue J; Liu C; Cao C; Zhong H; Ma Q
BMC Biotechnol; 2010 Dec; 10():91. PubMed ID: 21176167
[TBL] [Abstract][Full Text] [Related]
9. Designing and Analyzing the Structure of DT-STXB Fusion Protein as an Anti-tumor Agent: An
Mohseni Moghadam Z; Halabian R; Sedighian H; Behzadi E; Amani J; Imani Fooladi AA
Iran J Pathol; 2019; 14(4):305-312. PubMed ID: 31754360
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the interaction of superantigen with the alternative superantigen-binding receptor p85.
Rogers TJ; Zhang L
Mol Immunol; 1997 Feb; 34(3):263-72. PubMed ID: 9224968
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a recombinant double mutant of staphylococcal enterotoxin B (SEB-H32Q/K173E) with enhanced antitumor activity effects and decreased pyrexia.
Gu L; Yue J; Zheng Y; Zheng X; Wang J; Wang Y; Li J; Jiang Y; Jiang H
PLoS One; 2013; 8(2):e55892. PubMed ID: 23405232
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies defining functional sites on the toxin superantigen staphylococcal enterotoxin B.
Hamad AR; Herman A; Marrack P; Kappler JW
J Exp Med; 1994 Aug; 180(2):615-21. PubMed ID: 7519243
[TBL] [Abstract][Full Text] [Related]
13. Localization of binding sites of staphylococcal enterotoxin B (SEB), a superantigen, for HLA-DR by inhibition with synthetic peptides of SEB.
Komisar JL; Small-Harris S; Tseng J
Infect Immun; 1994 Nov; 62(11):4775-80. PubMed ID: 7927754
[TBL] [Abstract][Full Text] [Related]
14. Targeting the EGFR in cancer cells by fusion protein consisting of arazyme and third loop of TGF-alpha: an in silico study.
Ghadaksaz A; Imani Fooladi AA; Mahmoodzadeh Hosseini H; Nejad Satari T; Amin M
J Biomol Struct Dyn; 2022; 40(22):11744-11757. PubMed ID: 34379041
[TBL] [Abstract][Full Text] [Related]
15. Development of sandwich chemiluminescent immunoassay based on an anti-staphylococcal enterotoxin B Nanobody-Alkaline phosphatase fusion protein for detection of staphylococcal enterotoxin B.
Sun T; Zhao Z; Liu W; Xu Z; He H; Ning B; Jiang Y; Gao Z
Anal Chim Acta; 2020 Apr; 1108():28-36. PubMed ID: 32222241
[TBL] [Abstract][Full Text] [Related]
16. Staphylococcal enterotoxin B/texosomes as a candidate for breast cancer immunotherapy.
Imani Fooladi AA; Halabian R; Mahdavi M; Amin M; Mahmoodzadeh Hosseini H
Tumour Biol; 2016 Jan; 37(1):739-48. PubMed ID: 26245994
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms mediating enhanced neutralization efficacy of staphylococcal enterotoxin B by combinations of monoclonal antibodies.
Dutta K; Varshney AK; Franklin MC; Goger M; Wang X; Fries BC
J Biol Chem; 2015 Mar; 290(11):6715-30. PubMed ID: 25572397
[TBL] [Abstract][Full Text] [Related]
18. Major histocompatibility complex class I molecule serves as a ligand for presentation of the superantigen staphylococcal enterotoxin B to T cells.
Häffner AC; Zepter K; Elmets CA
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):3037-42. PubMed ID: 8610164
[TBL] [Abstract][Full Text] [Related]
19. Construction and characterization of a novel fusion protein MG7-scFv/SEB against gastric cancer.
Tong Q; Liu K; Lu XM; Shu XG; Wang GB
J Biomed Biotechnol; 2010; 2010():121094. PubMed ID: 20339532
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
